Fulcrum Therapeutics merges with Slate Medicines in $245m-backed deal
The all-stock merger sees Fulcrum rebuild following its pociredir discontinuation, with the combined entity focusing on SLTE-1009 — a monoclonal antibody in development for migraine and headache disorders — funded into 2029